Aurigene Pharmaceutical Services has the capability to synthesize and manufacture DuPHOS and BPE family of asymmetric hydrogenation ligands.
Catalysts derived from the bidentate DuPHOS and BPE ligands exhibit particularly high efficiency and selectivity in a wide spectrum of asymmetric hydrogenation reactions. These modular phospholane ligands can be tuned to ideally accommodate the steric demands of a given substrate to optimize the catalyst efficacy and provide access to a variety of chiral compounds containing C-N, C-O and C-C stereogenic centers.
We have close to 25 years of experience in developing these ligands and catalysts.
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.